Tissue-signaling research
KPV
Lyophilized immune-signaling research peptide for pathway review
KPV is an alpha-MSH fragment research peptide studied around epithelial integrity, immune signaling, and inflammatory-pathway models.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesAlleen voor laboratoriumonderzoek. Niet voor menselijk of diergeneeskundig gebruik. Niet bedoeld voor het diagnosticeren, behandelen, genezen, verzachten of voorkomen van ziekten.
Afgesloten, koud, droog en beschermd tegen hitteschommelingen bewaren. Bevestig productspecifieke opslag bij aankomst.
Verpakt voor stabiliteit tijdens het transport, met bestelondersteuning beschikbaar voor routes bij warm weer.
Batch-linked certificate support is available through the documentation desk.
Onderzoekscontext
KPV onderzoeksprofiel
KPV is the tripeptide Lys-Pro-Val, a short fragment derived from the carboxyl end of alpha-melanocyte-stimulating hormone. Preclinical research examines epithelial integrity, cytokine signaling, inflammatory-pathway markers, microbial interactions, and gut or skin model systems. Unlike broader melanocortin analogs, KPV is generally studied for fragment-specific activity and may not reproduce the full receptor profile of alpha-MSH. It is a focused choice for projects comparing short melanocortin-derived peptides in epithelial or immune-signaling experiments. Evidence is primarily laboratory and animal based, and reported pathway effects depend on the model, concentration, formulation, and endpoints used in the original study.
Voorgesteld mechanisme
A Lys-Pro-Val tripeptide derived from the C-terminal region of alpha-MSH. Proposed actions include cell entry through peptide transport systems and suppression of NF-kappaB, MAPK, cytokine, and microbial-response pathways, sometimes independently of classical melanocortin receptors.
In studies gerapporteerde effecten
- Cell studies reported reduced activation of inflammatory transcription pathways and lower production of selected cytokines.
- Animal and epithelial models reported reduced inflammation or tissue injury in selected gut, skin, and infection-related experiments.
- Mechanism, transport, and potency vary by model, and controlled human evidence is not established.
Veelgebruikte onderzoekseindpunten
NF-kappaB and MAPK activation, cytokines such as TNF-alpha and IL-6, epithelial permeability, histology, microbial growth, peptide transport, and tissue-injury scores.
Bewijs en beperkingen
Evidence is primarily cell and animal based. Human pharmacokinetics, efficacy, and safety remain insufficiently characterized.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.